Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.

Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S.

World J Gastroenterol. 2016 Sep 7;22(33):7569-78. doi: 10.3748/wjg.v22.i33.7569.

2.

Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response.

Lee HW.

Gut Liver. 2016 Sep 15;10(5):661-2. doi: 10.5009/gnl16340. No abstract available.

3.

Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.

Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF.

J Clin Exp Hepatol. 2016 Jun;6(2):100-8. doi: 10.1016/j.jceh.2016.02.006.

PMID:
27493457
4.

Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study.

Sawamoto R, Nagano J, Kajiwara E, Sonoda J, Hiramoto T, Sudo N.

Biopsychosoc Med. 2016 Jul 29;10:24. doi: 10.1186/s13030-016-0075-3.

5.

Management of HCV-Associated Liver Cirrhosis.

Schneider MD, Sarrazin C.

Visc Med. 2016 Apr;32(2):96-104. doi: 10.1159/000445330. Review.

PMID:
27413726
6.

Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis.

Maor Y, Malnick SD, Melzer E, Leshno M.

PLoS One. 2016 Jul 13;11(7):e0157832. doi: 10.1371/journal.pone.0157832.

7.

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.

Chidi AP, Bryce CL, Donohue JM, Fine MJ, Landsittel DP, Myaskovsky L, Rogal SS, Switzer GE, Tsung A, Smith KJ.

Value Health. 2016 Jun;19(4):326-34. doi: 10.1016/j.jval.2016.01.010.

PMID:
27325324
8.

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.

Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O.

Int J Med Sci. 2016 May 12;13(6):418-23. doi: 10.7150/ijms.15519.

9.

Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study.

Zeng QL, Li B, Zhang XX, Chen Y, Fu YL, Lv J, Liu YM, Yu ZJ.

Gut Liver. 2016 Nov 15;10(6):955-961. doi: 10.5009/gnl15321.

10.

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Al-Mahtab M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK.

Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3.

11.

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics.

Berenguer J, Rivero A, Jarrín I, Núñez MJ, Vivancos MJ, Crespo M, Téllez MJ, Domingo P, Iribarren JA, Artero A, Márquez M, Santos I, Moreno J, Montero M, González-García J.

Open Forum Infect Dis. 2016 Mar 11;3(2):ofw059. doi: 10.1093/ofid/ofw059.

12.

Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease.

Maan R, van der Meer AJ.

F1000Res. 2016 Mar 17;5. pii: F1000 Faculty Rev-367. doi: 10.12688/f1000research.7399.1. Review.

13.

Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C.

Hayashi T, Ogawa E, Furusyo N, Murata M, Hayashi J.

Infect Agent Cancer. 2016 Feb 24;11:9. doi: 10.1186/s13027-016-0056-y.

14.

Historical review of the causes of cancer.

Blackadar CB.

World J Clin Oncol. 2016 Feb 10;7(1):54-86. doi: 10.5306/wjco.v7.i1.54. Review.

15.

Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.

Simmons B, Saleem J, Hill A, Riley RD, Cooke GS.

Clin Infect Dis. 2016 Mar 15;62(6):683-94. doi: 10.1093/cid/civ948.

16.

Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.

Hartman J, Bichoupan K, Patel N, Chekuri S, Harty A, Dieterich D, Perumalswami P, Branch AD.

World J Gastroenterol. 2015 Nov 21;21(43):12430-8. doi: 10.3748/wjg.v21.i43.12430.

17.

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.

Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima A, Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.

Gut Liver. 2016 Jul 16;10(4):617-23. doi: 10.5009/gnl15193.

18.

Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance.

Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C.

World J Hepatol. 2015 Nov 8;7(25):2590-6. doi: 10.4254/wjh.v7.i25.2590. Review.

19.

Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.

Maan R, de Knegt RJ, Veldt BJ.

Drugs. 2015 Nov;75(17):1981-92. doi: 10.1007/s40265-015-0480-0. Review.

20.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group..

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013.

PMID:
26497081
Items per page

Supplemental Content

Support Center